Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics
出版年份 2015 全文链接
标题
Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics
作者
关键词
-
出版物
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 24, Issue 5, Pages 673-687
出版商
Informa Healthcare
发表日期
2015-01-20
DOI
10.1517/13543784.2015.1005736
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: A randomized controlled open-label trial
- (2014) A. Adenis et al. ANNALS OF ONCOLOGY
- A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors
- (2014) Carlos R. Becerra et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors
- (2014) E. Gabriela Chiorean et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Randomized Phase II Open-Label Study of mFOLFOX6 in Combination With Linifanib or Bevacizumab for Metastatic Colorectal Cancer
- (2014) Bert H. O'Neil et al. Clinical Colorectal Cancer
- Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients
- (2014) Olivier Huillard et al. Expert Opinion On Drug Safety
- Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer
- (2014) Audrey Bellesoeur et al. INVESTIGATIONAL NEW DRUGS
- Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Squamous Non–Small-Cell Lung Cancer: Results From the Randomized Controlled MONET1 Study
- (2014) Silvia Novello et al. Journal of Thoracic Oncology
- Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
- (2014) Martin Reck et al. LANCET ONCOLOGY
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial
- (2014) Robert J Motzer et al. LANCET ONCOLOGY
- Applying Synthetic Lethality for the Selective Targeting of Cancer
- (2014) Donal P. McLornan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nilotinib in Combination with Carboplatin and Paclitaxel Is a Candidate for Ovarian Cancer Treatment
- (2014) Marion T. Weigel et al. ONCOLOGY
- CP-673451, a platelet-derived growth-factor receptor inhibitor, suppresses lung cancer cell proliferation and migration
- (2014) Yuling Xi et al. OncoTargets and Therapy
- Lenvatinib Slows Progression of Thyroid Cancer
- (2014) Cancer Discovery
- A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy
- (2013) Przemyslaw W. Twardowski et al. ANTI-CANCER DRUGS
- Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia
- (2013) E. I. Zimmerman et al. BLOOD
- A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer
- (2013) Erica L. Mayer et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib
- (2013) Y-K Kang et al. BRITISH JOURNAL OF CANCER
- Phase I Study of Dovitinib (TKI258), an Oral FGFR, VEGFR, and PDGFR Inhibitor, in Advanced or Metastatic Renal Cell Carcinoma
- (2013) E. Angevin et al. CLINICAL CANCER RESEARCH
- Nilotinib for treatment of gastrointestinal stromal tumors: out of the equation?
- (2013) Tatsuo Kanda et al. EXPERT OPINION ON PHARMACOTHERAPY
- A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: A Gynecologic Oncology Group study
- (2013) R.J. Schilder et al. GYNECOLOGIC ONCOLOGY
- Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma
- (2013) Koji Matsuo et al. GYNECOLOGIC ONCOLOGY
- Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
- (2013) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Tobacco Cessation and Control a Decade Later: American Society of Clinical Oncology Policy Statement Update
- (2013) Nasser Hanna et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment-Related Toxicities in a Phase II Trial of Dasatinib in Patients with Squamous Cell Carcinoma of the Lung
- (2013) Andrew M. Brunner et al. Journal of Thoracic Oncology
- Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
- (2013) Thomas E Hutson et al. LANCET ONCOLOGY
- Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial
- (2013) John C Araujo et al. LANCET ONCOLOGY
- Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer
- (2013) B. M. Wolpin et al. ONCOLOGIST
- Phase II Study of Dasatinib (BMS-354825) in Patients With Metastatic Adenocarcinoma of the Pancreas
- (2013) C. E. Chee et al. ONCOLOGIST
- Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel
- (2013) John Araujo et al. Cancer Management and Research
- Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma
- (2012) Han Chong Toh et al. CANCER
- Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
- (2012) Douglas Hanahan et al. CANCER CELL
- Paracrine signalling in colorectal liver metastases involving tumor cell-derived PDGF-C and hepatic stellate cell-derived PAK-2
- (2012) Obul R. Bandapalli et al. CLINICAL & EXPERIMENTAL METASTASIS
- Crenolanib Inhibits the Drug-Resistant PDGFRA D842V Mutation Associated with Imatinib-Resistant Gastrointestinal Stromal Tumors
- (2012) M. C. Heinrich et al. CLINICAL CANCER RESEARCH
- Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
- (2012) Russell J. Schilder et al. GYNECOLOGIC ONCOLOGY
- International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer: MONET1
- (2012) Giorgio V. Scagliotti et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Stromal Platelet-Derived Growth Factor Receptor (PDGFR ) Provides a Therapeutic Target Independent of Tumor Cell PDGFR Expression in Lung Cancer Xenografts
- (2012) D. E. Gerber et al. MOLECULAR CANCER THERAPEUTICS
- Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors
- (2011) M. H. G. Langenberg et al. ANNALS OF ONCOLOGY
- E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion
- (2011) Hilary Glen et al. BMC CANCER
- Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study
- (2011) R. S. Finn et al. CLINICAL CANCER RESEARCH
- Biologic and Clinical Activity of Tivozanib (AV-951, KRN-951), a Selective Inhibitor of VEGF Receptor-1, -2, and -3 Tyrosine Kinases, in a 4-Week-On, 2-Week-Off Schedule in Patients with Advanced Solid Tumors
- (2011) F. A. L. M. Eskens et al. CLINICAL CANCER RESEARCH
- A Phase 2 Trial of Dasatinib in Patients with Advanced HER2-Positive and/or Hormone Receptor-Positive Breast Cancer
- (2011) E. L. Mayer et al. CLINICAL CANCER RESEARCH
- Sorafenib exposure decreases over time in patients with hepatocellular carcinoma
- (2011) Jennifer Arrondeau et al. INVESTIGATIONAL NEW DRUGS
- Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer
- (2011) Eng-Huat Tan et al. Journal of Thoracic Oncology
- Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer
- (2010) Emmanuel Mitry et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors
- (2010) Robert S. Benjamin et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors
- (2010) M. H. G. Langenberg et al. CLINICAL CANCER RESEARCH
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- ABT-869 Inhibits the Proliferation of Ewing Sarcoma Cells and Suppresses Platelet-Derived Growth Factor Receptor and c-KIT Signaling Pathways
- (2010) A. K. Ikeda et al. MOLECULAR CANCER THERAPEUTICS
- Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
- (2009) R Kumar et al. BRITISH JOURNAL OF CANCER
- PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment
- (2009) Yongping Crawford et al. CANCER CELL
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance
- (2009) Thomas O'Hare et al. CANCER CELL
- Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Oral CP-868,596, a Highly Specific Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitor in Patients With Advanced Cancers
- (2009) Nancy L. Lewis et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Dose Escalation Study of Telatinib, a Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor 2 and 3, Platelet-Derived Growth Factor Receptor β, and c-Kit, in Patients With Advanced or Metastatic Solid Tumors
- (2009) Ferry A.L.M. Eskens et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid Cancer
- (2009) Martin J. Schlumberger et al. JOURNAL OF CLINICAL ONCOLOGY
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
- (2009) Rafael Rosell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT
- (2009) Patrice Dubreuil et al. PLoS One
- Translation of the Philadelphia chromosome into therapy for CML
- (2008) B. J. Druker BLOOD
- Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours
- (2008) D Strumberg et al. BRITISH JOURNAL OF CANCER
- Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer
- (2008) P Mathew et al. BRITISH JOURNAL OF CANCER
- Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis
- (2008) Daniela Matei et al. CANCER
- BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
- (2008) F. Hilberg et al. CANCER RESEARCH
- Paracrine Signaling by Platelet-Derived Growth Factor-CC Promotes Tumor Growth by Recruitment of Cancer-Associated Fibroblasts
- (2008) C. Anderberg et al. CANCER RESEARCH
- Hypertension and Rarefaction during Treatment with Telatinib, a Small Molecule Angiogenesis Inhibitor
- (2008) N. Steeghs et al. CLINICAL CANCER RESEARCH
- Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
- (2008) D. D. Hu-Lowe et al. CLINICAL CANCER RESEARCH
- Role of platelet-derived growth factors in physiology and medicine
- (2008) J. Andrae et al. GENES & DEVELOPMENT
- Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs)
- (2008) T Negri et al. JOURNAL OF PATHOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now